{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-008651","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.973056+00:00","generated_at":"2026-05-18T09:36:16.179985+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tonix announces preclinical data for TNX-1700 in gastric cancer models published in Cancer Cell","bullets":["mTNX-1700 plus anti-PD-1 increased survival and decreased metastases in gastric cancer animal models vs anti-PD-1 alone.","Treatment associated with activation of CD8+ T cells and limiting neutrophil-mediated immune evasion.","Human version TNX-1700 (hTFF2-HSA) is in preclinical development for gastric and colorectal cancers.","Collaboration with Columbia University's Medical School; paper titled 'A CXCR4 Partial Agonist, Improves Immunotherapy...'.","Data support further development of TNX-1700 to overcome resistance to anti-PD-1 immunotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-008651","json":"https://secwatch.observer/filing/0001999371-25-008651.json","markdown":"https://secwatch.observer/filing/0001999371-25-008651.md","text":"https://secwatch.observer/filing/0001999371-25-008651.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125008651/0001999371-25-008651-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125008651/tnxp-8k_070225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:36:16.179985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}